Progyny, Inc.

PGNY Healthcare Healthcare Plans

Progyny, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 5.30%, EPS grew 80.0% and free cash flow fell 12.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

26.86 0.60 −2.18%
Market cap
$2.1B
P/E
27.7×
Fwd P/E
19.9×
Dividend yield
—
F-score
8/9
Altman Z
8.89
Beneish M
−3.45
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Revenue

+8 more TTM periods

1,268.69 1,288.66 1,293.13 1,310.76
Gross Profit
291.03 304.48 311.76 322.09
Operating Income
85.84 85.28 96.49 112.13
EBT
95.24 95.43 105.78 119.84
Income after Tax
56.57 58.52 67.69 78.63
Net Income Common
56.57 58.52 67.69 78.63
EPS (Diluted)
0.63 0.65 0.77 0.92
Shares (Diluted, Weighted)
91.16 89.76 88.62 86.75
Gross Margin
22.94% 23.63% 24.11% 24.57%
EBIT Margin
6.77% 6.62% 7.46% 8.55%
Net Profit Margin
4.46% 4.54% 5.23% 6.00%
Free Cash Flow Margin
15.25% 14.88% 14.26% 13.61%
EBITDA
93.62 90.23 101.81 117.87
EBIT
85.84 85.28 96.49 112.13

Show all line items

In millions of $ except per-share values · columns are period end dates